AstraZeneca’s stock market exit would be devastating blow, warns ex-chancellor - The UK is ‘a hostile environment’ for ...

Shares of AstraZeneca PLC AZN shed 1.66% to £104.50 Friday, on what proved to be an all-around dismal trading session for the ...

AstraZeneca PLC closed 20.63% short of its 52-week high of £133.88, which the company achieved on September 3rd.

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

AstraZeneca may have washed its hands of AZD4041 after the opioid use disorder (OUD) prospect demonstrated a potential drug-drug interaction last year, but the pharma’s development partner, Eolas T | ...

"attachment_1220866" align="aligncenter" width="1456"] A laboratory employee in a sterile environment inspecting a microscope ...

London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...